Drug intelligence / Profile preview

THVD-202

Development stage: Preclinical
Lead developer: TheraVida
Modality: Small Molecules

Overview

THVD-202 is a proprietary once-daily combination drug product candidate developed by TheraVida, Inc. for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). It is designed to offer a new treatment option with reduced dry mouth side effects. SK Chemicals Co. Ltd. has licensed exclusive rights to develop and commercialize THVD-202 in South Korea, where it is currently completing preclinical development.

Targets

CHRM3 (M3)CHRM2 (M2)

Beyond the preview

Go deeper on THVD-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THVD-202.

Explore the full profile